Skip to main content

Table 1 Demographic and clinical features of patients with RA according to Anti-PAD antibody status

From: Smoking is not linked to the development of anti-peptidylarginine deiminase 4 autoantibodies in rheumatoid arthritis

  PAD negative (P0) (N = 206) PAD4 Ab only (P4) (N = 34) PAD3/4 Ab (XR)
(N = 34)
p-value
P0 vs P4
p-value
P0 vs XR
p-value
P4 vs XR
Female sex- N (%) 163 (79%) 27 (79%) 28 (82%) 0.99 0.66 0.76
Race- N (%)     0.99 0.91 0.95
 Caucasian 165 (80%) 28 (82.4%) 27 (79%)    
 African American 27 (13%) 4 (11.8%) 4 (12%)    
 Asian/Other 14 (7%) 2 (6%) 3 (9%)    
Age- median (IQR) 57 (49–66) 55 (47–68) 51.5 (46–64) 0.70 0.14 0.33
Disease duration (yrs) - median (IQR) 6 (2–12) 15.5 (8–27) 15.5 (7–26) < 0.01 < 0.01 0.77
Ever smoking- N (%) 95 (47%) 16 (47%) 12 (35%) 0.96 0.22 0.32
Current smoking- N (%) 24 (12%) 3 (8.8%) 0 (0%) 0.62 0.04 0.08
CCP positive- N (%) 116 (57%) 30 (88.2%) 30 (88.2%) < 0.01 < 0.01 1.0
Shared Epitope- N (%) 112 (54%) 28 (82.4%) 22 (64.7%) < 0.01 0.26 0.10
Erosions- N (%)
N = 268
88 (43%) 17 (54.8%) 22 (65%) 0.24 0.02 0.42
CDAI- median (IQR) 7.9 (3–16) 7 (2.8–11.5) 3.7 (1.5–9.5) 0.37 0.04 0.21
On a DMARD- N (%) 184 (90%) 28 (82%) 28 (82%) 0.21 0.20 1.0
On methotrexate- N (%) 127 (63%) 20 (59%) 24 (71%) 0.73 0.33 0.31
On a biologic- N (%) 89 (44%) 17 (50%) 16 (47%) 0.49 0.71 0.81